Recent data and the FDA approval of tirzepatide have generated a lot excitement in the medical community about the role of this agent in the treatment of type 2 diabetes and obesity. In this podcast, CMHC Co-Chair Dr. Anne Peters, Professor of Medicine at the University of Southern California in LA, discusses the clinical implications of this agent and its potential role now and going forward.
Don't forget to rate, subscribe/follow, and leave us a 5-star review!
Cardiometabolic Beat Podcast